The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a National Cancer Institute-designated comprehensive cancer center, a distinction that places it in the top tier of cancer centers throughout the country. Located on the medical campus of the University of Maryland at Baltimore, UMGCCC brings together expert researchers and clinicians to collaborate on preventing, detecting, and treating cancer. As part of an academic medical community, UMGCCC integrates cutting-edge cancer treatment with leadership in cancer research and a commitment to medical education.
The mission of the UMGCCC is to undertake innovative basic, clinical, population and prevention research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond.
UMGCCC is a National Cancer Institute-designated comprehensive cancer center, a distinction that places it in the top tier of cancer centers throughout the country.
UMGCCC is ranked among the top cancer programs in the country, according to U.S. News & World Report’s Best Hospitals list.
Cancer research funding at UMGCCC has grown dramatically since 2002 — from $19.4 to $57.5 million — continues to drive scientific discovery by our cancer experts, all of whom are on the faculty of the University of Maryland School of Medicine.
UMGCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 30 percent of the patients in our clinical trials, compared to 2 percent nationally.
The Maryland Proton Treatment Center, opening in 2015 in the University of Maryland Biopark, is a next-generation radiation treatment facility expected to treat 2,000 cancer patients per year when fully operational.
A compound discovered by Dr. Angela Brodie and Dr. Vincent Njar is showing promise in clinical trials for treatment of the most advanced state of prostate cancer.
Dr. Stuart Martin discovered that “microtentacles” on breast cancer cells play a key role in how cancers spread in the body.
Dr. Angela Brodie discovered aromatase inhibitors for the treatment of breast cancer. Recent trials also showed that these drugs can prevent two thirds of cancers in women at high risk for developing the disease.
Dr. Kevin Cullen’s research demonstrated for the first time that racial survival disparities in head and neck cancer are largely explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection.
UMGCCC researchers are pioneering stem cell and HIV/AIDS related cancer studies in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology.
To read more about the Marlene and Stewart Greenebaum Comprehensive Cancer Center, visit www.umgccc.org.
Mr. Stuart Weitzman
Mrs. Marie G. Bowers
Mr. Keith Bozeman
The Honorable David R. Brinkley
Mr. Steven J. Colnitis
Jay C. Feinglass, DMD
Mr. S. Robert Ginsberg
Mrs. Sonya Z. Goodman
Mrs. Marlene Greenebaum
Mr. Stewart J. Greenebaum
Mr. Michael I. Greenebaum
Mr. Erik D. Johnson
Mr. Neil S. Kishter
Mr. Robert Marshall
Mrs. Donna M. Maykrantz
Mr. Lawrence F. Maykrantz
Mr. Jonathan P. Myers
Ms. Ricka E. Neuman, CPA
Mr. Ian H. Neuman
Mrs. Leslie Pomerantz
Ms. Paula R. Rome
Mr. Jonathan B. Sevel
Mr. C. Dale Springer, Jr.
Mrs. Roslyn Stoler
Mrs. Edith Wolpoff-Davis